Transcript
ReachMD Announcer:
You’re listening to ReachMD. This medical industry feature, titled “Exploring Perspectives on Speed of Onset for Dry Eye Treatment” is sponsored by Bausch + Lomb. Eye care professionals in this video received compensation for their time.
Here’s Dr. Marguerite McDonald, Dr. Jennifer Loh, and Dr. Kenneth Beckman.
Voiceover:
We asked a group of leading eye care professionals about the speed of onset their patients have experienced with Xiidra® (lifitegrast ophthalmic solution) 5%. This is what they had to say.
Dr. McDonald:
Xiidra is my preferred treatment to address inflammation in dry eye because the studies that led to the approval are so compelling and it kicks in very quickly.1*†
Dr. Loh:
Some of the things I like about Xiidra is the quick onset of action for the patient. In the clinical trials with Xiidra, they found symptom relief in as early as two weeks.1* And this is really important for my patients because, of course, they want to feel better faster.
Dr. Beckman:
I’ve actually been surprised at the number of patients I’ve had that have told me they had rapid relief from the medication.1* Even though we know the anti-inflammatory process is going to take weeks to months. I’ve been really pleasantly surprised with that.
Dr. McDonald:
There is no faster onset of action that I’m aware of. Nothing beats two weeks of speedy efficacy in onset of action.1*
Voiceover:
Please see the transcript for important notes, references and safety information.
*Xiidra significantly reduced symptoms of eye dryness at 2 weeks (based on Eye Dryness Score compared to vehicle) in 2 of 4 studies.1
†The exact mechanism of action of Xiidra in dry eye disease is not known.
References
- Xiidra. Prescribing information. Bausch & Lomb Inc.
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.
Important Safety Information
- Do not use Xiidra if you are allergic to any of its ingredients. Seek medical care immediately if you get any symptoms of an allergic reaction.
- Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
- In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
- To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
- Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
- Safety and efficacy in pediatric patients below the age of 17 years have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information at Xiidra-ecp.com
ReachMD Announcer:
This program was sponsored by Bausch + Lomb. If you missed any part of this discussion, visit Industry Features on ReachMD.com, where you can Be Part of the Knowledge.
©2025 Bausch + Lomb.XDR.0432.USA.24
